A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants

NCT03403348 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-64417184
DRUG: Placebo

Sponsor

Janssen BioPharma, Inc.